Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.39Last Year’s EPS
-0.6Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -23.53%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Neutral
The call outlined significant strategic shifts and growth potential through the SCN acquisition and pediatric product line, but financial challenges remain with declining service revenue, increased losses, and reduced cash reserves. The Rebis alliance's underperformance also highlights potential integration risks.Company Guidance
During the first quarter of 2025 earnings call, Vivos Therapeutics provided guidance on several key metrics and strategic developments. CEO Kirk Huntsman highlighted a significant pivot in their business model, focusing on creating alliances with or acquiring sleep medical providers to drive sales of their OSA treatment appliances and diversify revenue. Product sales, particularly in the pediatric guide appliance line, saw an 87% increase in arches shipped compared to the previous year, despite an 8% rise in product revenue due to lower price points. The company anticipates closing the acquisition of the Sleep Center of Nevada, which tests approximately 3,000 patients monthly for sleep disorders, within the next month or two. This acquisition is expected to be accretive to revenue and gross profit, with an anticipated net contribution margin of 50% or better. Vivos has signed a non-binding term sheet for a $7.5 million senior loan to support this acquisition and is actively seeking a $1.5 million equity infusion. The company also reported a $3.9 million net loss for the first quarter of 2025, with total revenue decreasing to $3 million from $3.4 million in the prior year, reflecting their strategic pivot and cost-cutting initiatives.Pediatric Guide Appliance Line Growth
Total arches shipped grew 87% from 1,996 in the same period last year to 3,736 this year. Product revenue for the quarter was up 8% due to lower price points on certain pediatric products.
SCN Acquisition Potential
Acquisition of the Sleep Center of Nevada is expected to close in the next month or two, potentially adding diagnostics and treatment revenue. SCN sees approximately 3,000 sleep patients a month.
Strategic Shift to Sleep Medical Providers
Transitioning to a model of creating strategic alliances or acquiring sleep medical providers to drive sales and diversify revenue.
Cost Reduction Initiatives
Sales and marketing expenses decreased from $700,000 to $400,000, and total operating expenses decreased by 5% compared to last year due to cost-cutting initiatives.
VVOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VVOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $3.06 | $2.54 | -16.99% |
Mar 31, 2025 | $2.85 | $2.63 | -7.72% |
Nov 14, 2024 | $3.12 | $2.84 | -8.97% |
Aug 14, 2024 | $2.37 | $2.25 | -5.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vivos Therapeutics (VVOS) report earnings?
Vivos Therapeutics (VVOS) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Vivos Therapeutics (VVOS) earnings time?
Vivos Therapeutics (VVOS) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VVOS EPS forecast?
VVOS EPS forecast for the fiscal quarter 2025 (Q2) is -0.39.